Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset

dc.contributor.author	Chebbi, Pramod Prahlad
dc.contributor.author	Vineeta Shobha
dc.contributor.author	Rao, Vijay K.
dc.contributor.author	Haridas, Vikram
dc.contributor.author	Ramya Janardana
dc.contributor.author	Benzeeta Pinto
dc.contributor.author	Sharath Kumar
dc.contributor.author	Patil, Abhishek
dc.contributor.author	Tekkatte, Roopa
dc.contributor.author	Salanke, Manasa
dc.contributor.author	Mahendranath K. M.
dc.date.accessioned	2024-07-23T11:13:54Z
dc.date.available	2024-07-23T11:13:54Z
dc.date.issued	2023-07
dc.identifier.citation	BMC Rheumatology. 2023 July; 7(1): 1-6.	en_US
dc.identifier.issn	2520-1026
dc.identifier.uri	http://dspace.sdmmedicalcollege.org:8080/xmlui/handle/123456789/2252
dc.language.iso	en	en_US
dc.publisher	BioMed Central Ltd	en_US
dc.subject	Autoimmune rheumatic diseases	en_US
dc.subject	SARS-CoV-2 infection	en_US
dc.subject	Concomitant tofacitinib treatment	en_US
dc.title	Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset	en_US
dc.type	Article	en_US